• Publications
  • Influence
Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial.
It is concluded that nafarelin is an effective agent for treating endometriosis and has few side effects other than hypoestrogenism. Expand
Lysosomal concept of menstrual bleeding in humans.
The most dynamic enzymorphologic changes occur during the late secretory phase and early menstrual bleeding, and are characterized by increase of Ac Pase staining within the intercellular spaces of the stromal and epithelial layer. Expand
Transdermal delivery of sex steroids for hormone replacement therapy and contraception. A review of principles and practice.
Transdermal systems have been developed for hormonal replacement therapy (HRT) and recently for contraception, and have been designed to supplement testosterone in hypogonadal men. Expand
The effect of naproxen-sodium on the prostaglandin concentrations of the menstrual blood and uterine "jet-washings" in dysmenorrheic women.
The premise of causal relationships between naproxen-Na treatment, decreased uterine prostaglandins, reduction of intrauterine pressure, and relief from dysmenorrehic pain was strenthened. Expand
Treatment of endometriosis with a potent agonist of gonadotropin-releasing hormone (nafarelin).
Naval administration of agonistic analogs of GnRH may represent a new treatment modality for endometriosis and provide prompt and near-complete relief from their painful symptoms of endometRIosis. Expand
Naproxen sodium, aspirin, and placebo in primary dysmenorrhea. Reduction of pain and blood levels of prostaglandin F2-alpha metabolite.
The study confirms that at the doses utilized in this study the analgesic properties of naproxen sodium are superior to those of the more conventional prostaglandin synthetase inhibitor, aspirin, and that pain relief is related to the inhibition of prostaglandsin synthesis. Expand
Dose-dependent inhibition of pituitary-ovarian function during administration of a gonadotropin-releasing hormone agonistic analog (nafarelin).
In conclusion, inhibition of pituitary-ovarian function by daily intranasal nafarelin administration is dose dependent and may lead to the development of a clinically acceptable contraceptive which consistently inhibits ovulation while maintaining serum estradiol levels sufficient to prevent osteoporosis. Expand
Efficacy and safety of nafarelin in the treatment of endometriosis.
  • M. Henzl, L. Kwei
  • Medicine
  • American journal of obstetrics and gynecology
  • 1 February 1990
Nafarelin was found to be as effective as danazol for the management of endometriosis, with a different and more favorable safety profile. Expand
Ablation of folliculogenesis in women by a single dose of gonadotropin-releasing hormone agonist: significance of time in cycle.
Repeated intermittent administration of nafarelin or other gonadotropin-releasing hormone agonists in the early follicular phase may prevent follicular maturation and ovulation and may be a practical approach to contraceptive development. Expand
Naproxen sodium in uterine pain following intrauterine contraceptive device insertion.
Noonroxen sodium appears to offer a new treatment modality for pain associated with IUD usage, and was statistically significantly superior to placebo in a double-blind parallel trial. Expand